Lucid Diagnostics Inc. (LUCD): Price and Financial Metrics
LUCD Price/Volume Stats
| Current price | $1.26 | 52-week high | $1.80 |
| Prev. close | $1.26 | 52-week low | $0.68 |
| Day low | $1.22 | Volume | 344,000 |
| Day high | $1.27 | Avg. volume | 860,994 |
| 50-day MA | $1.34 | Dividend yield | N/A |
| 200-day MA | $1.03 | Market Cap | 136.32M |
LUCD Stock Price Chart Interactive Chart >
Lucid Diagnostics Inc. (LUCD) Company Bio
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
LUCD Price Returns
| 1-mo | N/A |
| 3-mo | -20.75% |
| 6-mo | 26.13% |
| 1-year | 35.48% |
| 3-year | -43.50% |
| 5-year | N/A |
| YTD | 53.90% |
| 2024 | -41.94% |
| 2023 | 3.68% |
| 2022 | -74.67% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...